Influence of 5-FU joint HER family targeted drugs on proliferation of esophageal squamous carcinoma cell

ObjectiveTo observe the influence of conventional chemotherapy drugs combined with epidermal growth factor receptor (EGFR) targeted drug C225 and human epidermal growth factor receptor-2 (HER2) targeted drug trastuzumab on proliferation of squamous cell carcinoma of the esophagus HE-2 cell line.MethodsMethyl thiazolyl tetrazolium bromide (MTT) assay and flow cytometry were applied to detect the effects of fluorourcil (5-FU) combined with C225 or 5-FU combined with trastuzumab on the proliferation of HE-2 cells.ResultsThe in vitro experiments showed that after the treatments of 5-Fu combined with C225 for 24 hours and 48 hours,the inhibition rate of HE-2 cell proliferation was 45.29±0.16 and 70.63±0.10,significantly higher than those of 5-Fu combined with trastuzumab(33.02±0.19 and 50.08±0.20) (P<0.05 for all).With the treatment of 5-Fu combined with C225 for 24 hours and 48 hours,the apoposis rate of HE-2 cells was 15.47±1.62% and 26.89±1.12%,significantly higher than those of treatment of 5-FU combined with trastuzumab (7.34±0.88% and 15.56±0.97%) (P <0.05 for all).ConclusionThe targeted drug C225 combined with 5-FU for EGFR pathway shows a synergistic effect on inhibition of the proliferation in HE-2 cells and the signal pathway of EGFR could be as a target for the treatment of human esophageal carcinoma.